Testing if an Ayurvedic Medicine called REE LIVOK 100 can help Lower Fat in the Liver.

A Phase III, Prospective, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a Polyherbal Capsule REE LIVOK 100 in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD). - NIL

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/02/103292

Enrollment

Registered

2026-02-09

Start date

Unknown

Completion date

Unknown

Last updated

2026-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E713- Disorders of fatty-acid metabolism

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: Diagnosed with Evidence of Fatty Liver (Grade I or II) on Ultrasound. Elevated ALT/AST: Levels more than 1.5x upper limit of normal (but less than 5x).Non-Alcoholic: Alcohol consumption more than 20g per day (men) or more than 10g per day (women).

Exclusion criteria

Exclusion criteria: Chronic heavy alcohol use.

Design outcomes

Primary

Measure	Time frame
To evaluate the reduction in Liver Fat Grading (Grade I or II or III) via Ultrasonography (USG).Timepoint: At baseline and day 42.	—

Secondary

Measure	Time frame
To assess normalization of liver enzymes (ALT, AST, GGT). To monitor reduction in Lipid Profile (Total Cholesterol, Triglycerides). To evaluate clinical improvement in symptoms (fatigue, right upper quadrant heaviness). To assess safety via Renal Function Tests (KFT). Timepoint: At Baseline & Day 42.	—

Countries

India

Contacts

Public ContactDr M S Ramasamy PhD

SANJEEV BIOMEDICAL RESEARCH CENTRE PVT. LTD.,

msramasamy23@gmail.com9176049309

Outcome results